A practical reference on 方法验证: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-16 and is reviewed periodically as new material appears.
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
High Voltage Engineering Corporation accelerators originated with the electrostatic generator designed by MIT physicist Robert J. Van de Graaff. In an effort to split the atom, Van de Graaff devised a electrostatic method to accelerate and direct charged particles at high voltages. While constructing a high-voltage prototype accelerator in the early 1930s, Van de Graaff patented several technologies that would form part of the future company's technology base. MIT professor John G. Trump, an apprentice of Van de Graaff, focused on making the generators useful for cancer radiotherapy. In the 1930s, few hospitals could afford radium sources, available x-ray sources were insufficiently powerful, and both methods damaged healthy tissues. Trump proposed that the unlimited, controllable beam output of Van de Graaff devices could make treatment affordable and safer. He built a series of compact "supervoltage" (>1-megavolt) x-ray generators for local cancer hospitals and secured further patents for the smaller generators. Returning from his World War II leave, Trump received requests from several British hospitals for new cancer generators and decided a company could better fulfill further orders. He recruited Van de Graaff to serve as co-founder and chief scientist. Neither professor wished to leave MIT, so Trump brought in British physicist Denis M. Robinson as a third co-founder and president. In 1946, Trump approached his wartime colleague, MIT President Karl Compton, about supporting the venture.
Additionally, the economic conditions surrounding future interest rate hikes; which could put renewed pressure on valuations, complicate loan refinancing, and impede debt servicing could cause major dislocation in commercial real estate markets. However, the contribution to Europe's economy in 2012 can be estimated at €285 billion according to EPRA and INREV, not to mention social benefits of an efficient real estate sector. It is estimated that commercial property is responsible for securing around 4 million jobs across Europe. As of April 2025, commercial real estate confidence experienced its sharpest drop since the COVID-19 pandemic amid the Trump Administration's latest tariff policies, with positive sentiment falling from 126.5% in the latter half of 2024 to 87.9%, according to the 1Q 2025 Board of Governors Sentiment Index.
=== Microbiota === Probiotic bacteria found in kefir products include Lactobacillus acidophilus, Bifidobacterium bifidum, Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus helveticus, Lactobacillus kefiranofaciens, Lactococcus lactis, and Leuconostoc species. Lactobacilli in kefir may exist in concentrations varying from approximately 1 million to 1 billion colony-forming units per milliliter, and are the bacteria responsible for the synthesis of the polysaccharide kefiran. In addition to bacteria, kefir often contains strains of yeast that can metabolize lactose, such as Kluyveromyces marxianus, Kluyveromyces lactis, and Saccharomyces fragilis, as well as strains of yeast that do not metabolize lactose, including Saccharomyces cerevisiae, Torulaspora delbrueckii, and Kazachstania unispora. The nutritional significance of these strains is not currently known with certainty.
Sources: en.wikipedia.org
C2H2 + H2O → CH3CHO The mishandling Hg-containing waste stream of the Chisso process led to an environmental catastrophe causing Minamata disease. Ethylidene diacetate, a precursor to acetaldehyde and vinyl acetate, was also produced by a similar process. Some of these routes, once dominant, have been significantly displaced by the Pd-catalyzed Wacker process, a greener process that starts with ethylene. In general oxymercuration reactions of alkenes and alkynes using mercuric compounds proceed via organomercury intermediates. A related reaction forming phenols is the Wolffenstein–Böters reaction.
=== Selected articles === White, S. H. (1986). The physical nature of planar bilayer membranes. In Ion Channel Reconstitution (Chris Miller, Ed.). Plenum Press: New York. pp. 3–35. Wiener, M. C. and White, S. H. (1992). The structure of a fluid dioleoylphosphatidylcholine bilayer determined by joint refinement using x-ray and neutron diffraction data. III. The complete structure. Biophys. J. 61:434–447. White, S. H., Wimley, W. C., Ladokhin, A. S., and Hristova, K. (1998). Protein folding in membranes: Determining the energetics of peptide–bilayer interactions. Methods Enzymol. 295:62–87. White, S. H. and Wimley, W. C. (1999). Membrane protein folding and stability: Physical principles. Annu. Rev. Biophys. Biomolec. Struct. 28:319–365 Hessa, T., Meindl-Beinker, N. M., Bernsel, A., Kim, H., Sato, Y., Lerch, M. B., Nilsson, I., White, S. H., and von Heijne, G. (2007). The molecular code for transmembrane-helix recognition by the Sec61 translocon. Nature 450:1026-1030. Cymer, F., von Heijne, G., & White S.H. (2015). Mechanisms of integral membrane protein insertion and folding. J Mol Biol 427:999-1022. Roussel, G., Lindner, E., & White, S. H. (2022). Topology of the SecA ATPase Bound to Large Unilamellar Vesicles. Journal of Molecular Biology, 434(12), 167607.
== Surface energy determination == The main application of IGC is to measure the surface energy of solids (fibers, particulates, and films). Surface energy is defined as the amount of energy required to create a unit area of a solid surface; analogous to surface tension of a liquid. Also, the surface energy can be defined as the excess energy at the surface of a material compared to the bulk. The surface energy (γ) is directly related to the thermodynamic work of adhesion (Wadh) between two materials as given by the following equation:
Those exposed to the TCE-contaminated water had a 70% higher risk of developing Parkinson's disease decades later, compared to veterans who trained at other locations. On January 9, 2023, the United States Environmental Protection Agency (EPA) concluded that TCE presents an unreasonable risk of causing injury to human health. In December 2024 the EPA issued a final rule to ban the use of trichloroethylene. However, under the Trump administration, this has been delayed.
Sources: en.wikipedia.org
Artificial gene synthesis, or simply gene synthesis, refers to a group of methods that are used in synthetic biology to construct and assemble genes from nucleotides de novo. Unlike DNA synthesis in living cells, artificial gene synthesis does not require template DNA, allowing virtually any DNA sequence to be synthesized in the laboratory. It comprises two main steps, the first of which is solid-phase DNA synthesis, sometimes known as DNA printing. This produces oligonucleotide fragments that are generally under 200 base pairs. The second step then involves connecting these oligonucleotide fragments using various DNA assembly methods. Because artificial gene synthesis does not require template DNA, it is theoretically possible to make a completely synthetic DNA molecule with no limits on the nucleotide sequence or size. Synthesis of the first complete gene, a yeast tRNA, was demonstrated by Har Gobind Khorana and coworkers in 1972. Synthesis of the first peptide- and protein-coding genes was performed in the laboratories of Herbert Boyer and Alexander Markham, respectively. More recently, artificial gene synthesis methods have been developed that will allow the assembly of entire chromosomes and genomes. The first synthetic yeast chromosome was synthesised in 2014, and entire functional bacterial chromosomes have also been synthesised. In addition, artificial gene synthesis could in the future make use of novel nucleobase pairs (unnatural base pairs).
== Use in organic synthesis == Without the propionyl group on the oxygen, the non-esterified alcohol precursor of propoxyphene (both enantiomers, known as darvon alcohol and novrad alcohol) have been employed as stoichiometric chiral reagents for asymmetric carbonyl reduction reactions involving aluminium hydride reagents.
== History == Mycophenolic acid was discovered by Italian medical scientist Bartolomeo Gosio. Gosio collected a fungus from spoiled corn and named it Penicillium glaucum. (The species is now called P. brevicompactum.) In 1893 he found that the fungus had antibacterial activity. In 1896 he isolated crystals of the compound, which he successfully demonstrated as the active antibacterial compound against the anthrax bacterium. This was the first antibiotic that was isolated in pure and crystalline form. But the discovery was forgotten. It was rediscovered by two American scientists C.L. Alsberg and O.M. Black in 1912, and given the name mycophenolic acid. The compound was eventually demonstrated to have antiviral, antifungal, antibacterial, anticancer, and antipsoriasis activities. Although it is not commercialised as antibiotic due to its adverse effects, its modified compound (ester derivative) is an approved immunosuppressant drug in kidney, heart, and liver transplantations, and is marketed under the brands Cellcept (mycophenolate mofetil by Roche) and Myfortic (mycophenolate sodium by Novartis). Cellcept was developed by a South African geneticist Anthony Allison and his wife Elsie M. Eugui. In the 1970s while working at the Medical Research Council, Allison investigated the biochemical causes of immune deficiency in children. He discovered the metabolic pathway involving an enzyme, inosine monophosphate dehydrogenase, which is responsible for undesirable immune response in autoimmune diseases, as well as for immune rejection in organ transplantation.
Phosphofructokinase is an important control point in the glycolytic pathway, since it is one of the irreversible steps and has key allosteric effectors, AMP and fructose 2,6-bisphosphate (F2,6BP). F2,6BP is a very potent activator of phosphofructokinase (PFK-1) that is synthesized when F6P is phosphorylated by a second phosphofructokinase (PFK2). In the liver, when blood sugar is low and glucagon elevates cAMP, PFK2 is phosphorylated by protein kinase A. The phosphorylation inactivates PFK2, and another domain on this protein becomes active as fructose bisphosphatase-2, which converts F2,6BP back to F6P. Both glucagon and epinephrine cause high levels of cAMP in the liver. The result of lower levels of liver F2,6BP is a decrease in activity of phosphofructokinase and an increase in activity of fructose 1,6-bisphosphatase, so that gluconeogenesis (in essence, "glycolysis in reverse") is favored. This is consistent with the role of the liver in such situations, since the response of the liver to these hormones is to release glucose to the blood. ATP competes with AMP for the allosteric effector site on the PFK enzyme. ATP concentrations in cells are much higher than those of AMP, typically 100-fold higher, but the concentration of ATP does not change more than about 10% under physiological conditions, whereas a 10% drop in ATP results in a 6-fold increase in AMP. Thus, the relevance of ATP as an allosteric effector is questionable. An increase in AMP is a consequence of a decrease in energy charge in the cell.
== Clinical significance == Several studies resulting in an initial information search on C3orf52 focused on the likely involvement of this gene in lipase H-mediated lysophosphatidic acid biosynthesis, a step in hair-follicle formation. Evidence shows that decreased expression of C3orf52 has been linked to localized autosomal recessive hypotrichosis, a condition resulting in the absence of hair. There were three relevant single-nucleotide polymorphisms found with clinical significance linked to hypotrichosis 15 (rs764787339, rs2472299130, rs545208237) (Table 2). Apart from articles on the involvement of C3orf52 in hair loss, PubMed and Google Scholar provided a couple of other potential linkages between this gene and diseases, specifically a variety of cancers. One of the more eye-catching articles found associations of this gene in the development of multifocal and multicentric breast cancer, and is looking into it as a current marker for distinguishing multifocal and multicentric breast cancer from unifocal breast cancers. Another study proposes looking at C3orf52 as a potential marker as a prognosis gene of cancer in a study looking at DNA copy number variations, which are common in cancer cells. Additionally, C3orf52 is linked to be downregulated in clear-cell renal cell carcinoma, and its reduced expression was linked to later disease stage and poorer overall survival of clear-cell renal cell carcinoma patients.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.